iRhythm beats Q2 estimates, buys VitalConnect for $287.5 million

iRhythm Technologies beat second-quarter estimates and raised its full-year outlook, while agreeing to buy VitalConnect for $287.5 million to broaden its cardiac monitoring portfolio beyond its Zio patch.

"Our second quarter results reflect strong execution across the business, with broad-based growth, meaningful margin expansion, and continued progress against our strategic priorities," Quentin Blackford, president and chief executive officer of iRhythm, said.

Revenue rose 20.1 percent to $224.2 million, topping the $219.2 million consensus by 2.3 percent. Adjusted earnings of $0.58 per share swung from a $0.32 loss a year earlier, while adjusted EBITDA reached $43.3 million, a 19.3 percent margin versus 8.4 percent in the prior-year quarter. Gross margin widened 160 basis points to 72.8 percent.

The company lifted its full-year revenue guidance to $880 million to $890 million and kept a 15 percent adjusted EBITDA margin target for 2027. Shares rose 3.1 percent to $132, giving the San Francisco-based company a market value of about $4.1 billion.

VitalConnect Deal Expands the Care Continuum

The acquisition, expected to close by the end of 2026, adds VitalConnect's FDA-cleared wearable biosensor platform spanning mobile cardiac telemetry and multi-vitals monitoring for hospital and remote care. iRhythm will pay $237.5 million in cash from its balance sheet plus about $50 million in stock, and provide up to $30 million in interim working capital financing.

The deal broadens iRhythm's reach beyond ambulatory monitoring into inpatient and hospital-to-home settings, where its Zio patch has limited presence. VitalConnect's platform tracks up to 11 physiological parameters, giving iRhythm a path into adjacent cardiovascular markets. Management expects the combination to add to revenue growth beginning in 2027.

The move comes as competition intensifies in remote cardiac monitoring. Philips' BioTelemetry and Boston Scientific's Preventice Solutions both sell patch-based monitors, while Baxter's BardyDx and Welch Allyn units have challenged iRhythm in court. iRhythm paid $50 million on July 31 to settle that patent litigation, which had weighed on operating expenses.

FDA Clearance Cuts Review Time

iRhythm also secured FDA clearance for its third-generation algorithm, which the company says will cut clinician review time by about 50 percent over time and generate roughly $100 million in cumulative cost savings over five years. The efficiency gain supports the margin expansion that underpins the 2027 target.

The company ended the quarter with $591.3 million in unrestricted cash and marketable securities, enough to fund the cash portion of the deal while preserving liquidity for its $661.2 million in convertible notes due 2029.

iRhythm shares, which trade at roughly 31 times forward earnings, have climbed about 21 percent this year as the company moved past a 2023 FDA warning letter and returned to profitability on an adjusted basis. The VitalConnect deal and algorithm clearance give investors two levers to watch: whether the acquisition closes on schedule and whether the cost savings materialize as projected.

This article is for informational purposes only and does not constitute investment advice.